Real-World Outcomes of Brexucabtagene Autoleucel for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia: Evidence From The CIBMTR Registry

Evandro Bezerra, MD¹; Taha Itani, PhD, MPH²; Kistada Wudhikarn, MD³; Miguel-Angel Perales, MD³; Yang Yang, MD⁴; Usama Gergis, MD, MBA⁴; Ahmed Aribi, MD⁵; LaQuisa C. Hill, MD⁶; Nitin Jain, MD⁷; Jessica T. Leonard, MD⁸; Forat Lutfi, MD⁹; Soyoung Kim, PhD¹⁰; Matthew Bye, MPH¹⁰; Hai-Lin Wang, MPH²; Tsveta Hadjivassileva, PhD²; Liana Nikolaenko, MD²; Ioana Kloos, MD, FRCPC²; Amina Abdeldaim, MD, MPH²; David Dalton, PharmD²; Hairong Xu, MD, PhD²; Marcelo Pasquini, MD, MS¹⁰; and Partow Kebriaei, MD⁷

¹The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ²Kite, a Gilead Company, Santa Monica, CA, USA;
 ³Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁴Thomas Jefferson University, Philadelphia, PA, USA;
 ⁵City of Hope, Duarte, CA, USA; ⁶Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA;
 ⁷The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
 ⁸Oregon Health and Science University, Portland, OR, USA; ⁹University of Kansas Medical Center, Kansas City, KS, USA;
 ¹⁰Center for International Blood and Marrow Transplant Research (CIBMTR), and Medical College of Wisconsin, Milwaukee, WI, USA.



The CIBMTR[®] (Center for International Blood and Marrow Transplant Research[®]) is a research collaboration between the National Marrow Donor Program[®] (NMDP)/Be The Match[®] and the Medical College of Wisconsin (MCW).

CIBMTR[®] & Kite, a Gilead Company Collaboration Study

 Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of adults with R/R B-ALL (≥18 years for US and ≥26 years for EU), based on results from the pivotal Phase 1/2, multicenter, single-arm ZUMA-3 study^{1,2}

1. TECARTUS® (brexucabtagene autoleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; 2021. 2. TECARTUS® (brexucabtagene autoleucel) [summary of product characteristics]. Amsterdam, The Netherlands: Kite Pharma EU B.V.; 2023. 3. Hadjivassileva T, et al. EU CAR T 2023. Abstract 34. 4. Roloff G, et al. J Clin Oncol. 2023;41:555-567.

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete hematological recovery; EU, European Union; OS, overall survival; R/R, relapsed or refractory; US, United States.

- Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of adults with R/R B-ALL (≥18 years for US and ≥26 years for EU), based on results from the pivotal Phase 1/2, multicenter, single-arm ZUMA-3 study^{1,2}
 - Brexu-cel demonstrated high CR/CRi rates in patients with R/R ALL in both ZUMA-3 (73%) and real-world settings (91%)^{3,4}
 - Additionally, responders in ZUMA-3 had a median OS of 47.0 months after 3 years of follow-up³

1. TECARTUS® (brexucabtagene autoleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; 2021. 2. TECARTUS® (brexucabtagene autoleucel) [summary of product characteristics]. Amsterdam, The Netherlands: Kite Pharma EU B.V.; 2023. 3. Hadjivassileva T, et al. EU CAR T 2023. Abstract 34. 4. Roloff G, et al. J Clin Oncol. 2023;41:555-567.

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete hematological recovery; EU, European Union; OS, overall survival; R/R, relapsed or refractory; US, United States.

- Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of adults with R/R B-ALL (≥18 years for US and ≥26 years for EU), based on results from the pivotal Phase 1/2, multicenter, single-arm ZUMA-3 study^{1,2}
 - Brexu-cel demonstrated high CR/CRi rates in patients with R/R ALL in both ZUMA-3 (73%) and real-world settings (91%)^{3,4}
 - Additionally, responders in ZUMA-3 had a median OS of 47.0 months after 3 years of follow-up³
- In real-world settings, patients treated with brexu-cel may have disease characteristics and treatment histories that are broader than the eligibility criteria used for ZUMA-3⁴

1. TECARTUS[®] (brexucabtagene autoleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; 2021. 2. TECARTUS[®] (brexucabtagene autoleucel) [summary of product characteristics]. Amsterdam, The Netherlands: Kite Pharma EU B.V.; 2023. 3. Hadjivassileva T, et al. EU CAR T 2023. Abstract 34. 4. Roloff G, et al. *J Clin Oncol*. 2023;41:555-567.

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete hematological recovery; EU, European Union; OS, overall survival; R/R, relapsed or refractory; US, United States.

- Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of adults with R/R B-ALL (≥18 years for US and ≥26 years for EU), based on results from the pivotal Phase 1/2, multicenter, single-arm ZUMA-3 study^{1,2}
 - Brexu-cel demonstrated high CR/CRi rates in patients with R/R ALL in both ZUMA-3 (73%) and real-world settings (91%)^{3,4}
 - Additionally, responders in ZUMA-3 had a median OS of 47.0 months after 3 years of follow-up³
- In real-world settings, patients treated with brexu-cel may have disease characteristics and treatment histories that are broader than the eligibility criteria used for ZUMA-3⁴
- Here we evaluated the effectiveness and safety outcomes of brexu-cel in a broad, real-world US patient population

^{1.} TECARTUS® (brexucabtagene autoleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; 2021. 2. TECARTUS® (brexucabtagene autoleucel) [summary of product characteristics]. Amsterdam, The Netherlands: Kite Pharma EU B.V.; 2023. 3. Hadjivassileva T, et al. EU CAR T 2023. Abstract 34. 4. Roloff G, et al. *J Clin Oncol*. 2023;41:555-567. B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete hematological recovery; EU,

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete hematological recovery; EU, European Union; OS, overall survival; R/R, relapsed or refractory; US, United States.

Study Design and Analysis

Prospective	 Data were prospectively collected as part of a PASS through the CIBMTR[®] registry of adult patients with R/R^a B-ALL treated with brexu-cel post-authorization between 2021 and 2023
Cohort Study	 Data cutoff: June 23, 2023 Median follow-up: 6.1 months

^a Relapse is defined as the recurrence of disease after CR, meeting ≥ 1 of the following criteria: $\geq 5\%$ BM blasts in marrow, extramedullary disease, or disease presence determined by physician upon clinical assessment. ^b CR/CRi was defined as having the following criteria for ≥ 4 weeks: <5% blasts in BM; normal maturation of all cellular components in BM; no extramedullary disease; ANC $\geq 1000/\mu$ L (CR only); platelets $\geq 100,000/\mu$ L (CR only); and transfusion independent. ^c Prolonged cytopenia is defined as having either prolonged Grade 4 neutropenia (failure to recover ANC $\geq 500/mm^3$ ($0.5 \times 10^9/L$) and/or sustain 3 lab values within the first 30 days after infusion) or prolonged Grade 4 thrombocytopenia (failure to recover platelet count $\geq 20 \times 10^9/L$ within the first 30 days after infusion). 1. Lee DW, et al. *Biol Blood Marrow Transplant*. 2019;25:625-638. alloSCT, allogeneic stem cell transplant; ANC, absolute neutrophil count; ASTCT, American Society for Transplantation and Cellular Therapy; B-ALL, B-cell acute lymphocytic leukemia; BM, bone marrow; ANC, absolute neutrophil count; brexu-cel, brexucabtagene autoleucel; CIBMTR, Center for International Blood and Marrow Transplant Research; CNS, central nervous system; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; DOR, duration of remission; ICANS, immune effector cell–associated neurotoxicity syndrome; MRD, minimal residual disease; OS, overall survival; PASS, post-authorization safety study; R/R, relapsed/refractory; RFS, relapse-free survival.

Study Design and Analysis

Prospective Cohort Study	 Data were prospectively collected as part of a PASS through the CIBMTR[®] registry of adult patients with R/R^a B-ALL treated with brexu-cel post-authorization between 2021 and 2023 Data cutoff: June 23, 2023 Median follow-up: 6.1 months
Outcomes of Interest	 Effectiveness: CR/CRi rate (primary), DOR, RFS, and OS Safety: CRS and ICANS (per ASTCT consensus¹), prolonged cytopenias^c


^a Relapse is defined as the recurrence of disease after CR, meeting ≥ 1 of the following criteria: $\geq 5\%$ BM blasts in marrow, extramedullary disease, or disease presence determined by physician upon clinical assessment. ^b CR/CRi was defined as having the following criteria for ≥ 4 weeks: <5% blasts in BM; normal maturation of all cellular components in BM; no extramedullary disease; ANC $\geq 1000/\mu$ L (CR only); platelets $\geq 100,000/\mu$ L (CR only); and transfusion independent. ^c Prolonged cytopenia is defined as having either prolonged Grade 4 neutropenia (failure to recover ANC $\geq 500/mm^3$ ($0.5 \times 10^9/L$) and/or sustain 3 lab values within the first 30 days after infusion) or prolonged Grade 4 thrombocytopenia (failure to recover platelet count $\geq 20 \times 10^9/L$ within the first 30 days after infusion). 1. Lee DW, et al. *Biol Blood Marrow Transplant*. 2019;25:625-638. alloSCT, allogeneic stem cell transplant; ANC, absolute neutrophil count; ASTCT, American Society for Transplantation and Cellular Therapy; B-ALL, B-cell acute lymphocytic leukemia; BM, bone marrow; ANC, absolute neutrophil count; brexu-cel, brexucabtagene autoleucel; CIBMTR, Center for International Blood and Marrow Transplant Research; CNS, central nervous system; CR, complete remission; CRi, coverall survival; PASS, post-authorization safety study; R/R, relapsed/refractory; RFS, relapse-free survival.

Study Design and Analysis

Prospective Cohort Study	 Data were prospectively collected as part of a PASS through the CIBMTR[®] registry of adult patients with R/R^a B-ALL treated with brexu-cel post-authorization between 2021 and 2023 Data cutoff: June 23, 2023 Median follow-up: 6.1 months 		
Outcomes of Interest	 • Effectiveness: CR/CRi rate (primary), DOR, RFS, and OS • Safety: CRS and ICANS (per ASTCT consensus¹), prolonged cytopenias^c 		
Statistical Analysis	 Time-to-event outcomes were analyzed using the Kaplan-Meier method Descriptive statistics are reported Descriptive subgroup analyses included: age (<60 and ≥60 years; <26 and ≥26 years), prior treatment (blinatumomab, yes or no; alloSCT, yes or no), disease status prior to infusion (extramedullary disease, yes or no; CNS disease, yes or no), and MRD status prior to infusion (CR/CRi^b MRD+, CR/CRi^b MRD-, and not in CR/CRi^b) 		

^a Relapse is defined as the recurrence of disease after CR, meeting ≥1 of the following criteria: ≥5% BM blasts in marrow, extramedullary disease, or disease presence determined by physician upon clinical assessment. ^b CR/CRi was defined as having the following criteria for ≥4 weeks: <5% blasts in BM; normal maturation of all cellular components in BM; no extramedullary disease; ANC ≥1000/µL (CR only); platelets ≥100,000/µL (CR only); platelets ≥100,000/µL (CR only); and transfusion independent. ^c Prolonged cytopenia is defined as having either prolonged Grade 4 neutropenia (failure to recover ANC ≥500/mm³ (0.5×10⁹/L) and/or sustain 3 lab values within the first 30 days after infusion) or prolonged Grade 4 thrombocytopenia (failure to recover platelet count ≥20×10⁹/L within the first 30 days after infusion). 1. Lee DW, et al. *Biol Blood Marrow Transplant*. 2019;25:625-638. alloSCT, allogeneic stem cell transplant; ANC, absolute neutrophil count; ASTCT, American Society for Transplantation and Cellular Therapy; B-ALL, B-cell acute lymphocytic leukemia; BM, bone marrow; ANC, absolute neutrophil count; brexu-cel, brexucabtagene autoleucel; CIBMTR, Center for International Blood and Marrow Transplant Research; CNS, central nervous system; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; DOR, duration of remission; ICANS, immune effector cell–associated neurotoxicity syndrome; MRD, minimal residual disease; OS, overall survival; PASS, post-authorization safety study; R/R, relapsed/refractory; RFS, relapse-free survival.

Study Cohort and Patient Disposition



Effectiveness and Safety Analysis Set **N=150** 80 patients excluded due to not having 100-day follow-up assessment completed at data cutoff (June 23, 2023)

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CIBMTR, Center for International Blood and Marrow Transplant Research; R/R, relapsed/refractory.

Characteristic	Patients (N=150)
Median age (range), years	42.9 (19.4-79.4)
≥26 years / ≥60 years, n (%)	139 (93) / 28 (19)
Race/Ethnicity	
Non-Hispanic White, n (%)	78 (52)
Non-Hispanic Black, n (%)	16 (11)
Non-Hispanic Asian, n (%)	9 (6)
Hispanic, n (%)	40 (27)
Not reported, n (%)	7 (5)
Cytogenic risk score of poor at diagnosis	84 (56)
Median number of prior lines of therapy, no. (range)	4 (1-13)
Prior blinatumomab, n (%)	77 (51)
Prior inotuzumab, n (%)	61 (41)
Prior alloSCT, n (%)	52 (35)

Characteristic	Patients (N=150)
Median age (range), years	42.9 (19.4-79.4)
≥26 years / ≥60 years, n (%)	139 (93) / 28 (19)
Race/Ethnicity	
Non-Hispanic White, n (%)	78 (52)
Non-Hispanic Black, n (%)	16 (11)
Non-Hispanic Asian, n (%)	9 (6)
Hispanic, n (%)	40 (27)
Not reported, n (%)	7 (5)
Cytogenic risk score of poor at diagnosis	84 (56)
Median number of prior lines of therapy, no. (range)	4 (1-13)
Prior blinatumomab, n (%)	77 (51)
Prior inotuzumab, n (%)	61 (41)
Prior alloSCT, n (%)	52 (35)

Characteristic	Patients (N=150)
Median age (range), years	42.9 (19.4-79.4)
≥26 years / ≥60 years, n (%)	139 (93) / 28 (19)
Race/Ethnicity	
Non-Hispanic White, n (%)	78 (52)
Non-Hispanic Black, n (%)	16 (11)
Non-Hispanic Asian, n (%)	9 (6)
Hispanic, n (%)	40 (27)
Not reported, n (%)	7 (5)
Cytogenic risk score of poor at diagnosis	84 (56)
Median number of prior lines of therapy, no. (range)	4 (1-13)
Prior blinatumomab, n (%)	77 (51)
Prior inotuzumab, n (%)	61 (41)
Prior alloSCT, n (%)	52 (35)

Characteristic	Patients(N=150)
Extramedullary disease prior to infusion, n (%)	32 (21)
CNS involvement prior to infusion, n (%)	14 (9)
MRD status prior to infusion ^{a,b}	
CR/CRi, MRD–	36 (24)
CR/CRi, MRD+	11 (7)
Not in CR/CRi	96 (64)
Not reported	7 (13)
% BM blast prior to infusion ^a	
≥0 to <5 / ≥5 to ≤25, n (%)	65 (43) / 14 (9)
>25 to ≤50 / >50, n (%)	7 (5) / 14 (9)
Not reported	50 (33)
Received bridging therapy, n (%)	61 (41)
ZUMA-3 ineligible, n (%)	135 (90)

Characteristic	Patients(N=150)	
Extramedullary disease prior to infusion, n (%)	32 (21)	
CNS involvement prior to infusion, n (%)	14 (9)	
MRD status prior to infusion ^{a,b}		
CR/CRi, MRD–	36 (24)	
CR/CRi, MRD+	11 (7)	
Not in CR/CRi	96 (64)	
Not reported	7 (13)	
% BM blast prior to infusion ^a		
≥0 to <5 / ≥5 to ≤25, n (%)	65 (43) / 14 (9)	
>25 to ≤50 / >50 <i>,</i> n (%)	7 (5) / 14 (9)	
Not reported	50 (33)	
Received bridging therapy, n (%)	61 (41)	
ZUMA-3 ineligible, n (%)	135 (90)	

Characteristic	Patients(N=150)
Extramedullary disease prior to infusion, n (%)	32 (21)
CNS involvement prior to infusion, n (%)	14 (9)
MRD status prior to infusion ^{a,b}	
CR/CRi, MRD–	36 (24)
CR/CRi, MRD+	11 (7)
Not in CR/CRi	96 (64)
Not reported	7 (13)
% BM blast prior to infusion ^a	
≥0 to <5 / ≥5 to ≤25, n (%)	65 (43) / 14 (9)
>25 to ≤50 / >50 <i>,</i> n (%)	7 (5) / 14 (9)
Not reported	50 (33)
Received bridging therapy, n (%)	61 (41)
ZUMA-3 ineligible, n (%)	135 (90)

Characteristic	Patients(N=150)
Extramedullary disease prior to infusion, n (%)	32 (21)
CNS involvement prior to infusion, n (%)	14 (9)
MRD status prior to infusion ^{a,b}	
CR/CRi, MRD–	36 (24)
CR/CRi, MRD+	11 (7)
Not in CR/CRi	96 (64)
Not reported	7 (13)
% BM blast prior to infusion ^a	
≥0 to <5 / ≥5 to ≤25, n (%)	65 (43) / 14 (9)
>25 to ≤50 / >50 <i>,</i> n (%)	7 (5) / 14 (9)
Not reported	50 (33)
Received bridging therapy, n (%)	61 (41)
ZUMA-3 ineligible, n (%)	135 (90)

Characteristic	Patients(N=150)
Extramedullary disease prior to infusion, n (%)	32 (21)
CNS involvement prior to infusion, n (%)	14 (9)
MRD status prior to infusion ^{a,b}	
CR/CRi, MRD–	36 (24)
CR/CRi, MRD+	11 (7)
Not in CR/CRi	96 (64)
Not reported	7 (13)
% BM blast prior to infusion ^a	
≥0 to <5 / ≥5 to ≤25, n (%)	65 (43) / 14 (9)
>25 to ≤50 / >50 <i>,</i> n (%)	7 (5) / 14 (9)
Not reported	50 (33)
Received bridging therapy, n (%)	61 (41)
ZUMA-3 ineligible, n (%)	135 (90)

- Most patients included in this analysis (90%) would have been ineligible for the ZUMA-3 study
- The most prevalent reasons patients would have been ineligible for ZUMA-3 included:
 - BM blasts <5% prior to infusion (43%)
 - Platelet count <50,000/µL (33%);
 - Moderate to severe pulmonary disease^a (32%)
 - Cardiovascular/cerebrovascular/heart valve disease^a (17%)

^a Aligned with Hematopoietic Cell Transplantation-specific Comorbidity index criteria. BM, bone marrow.

		. of Patients witl or CRi/Total No		CR/CRi Rate (95% CI)
Overall (N=150)		117/149	⊢	0.79 (0.71-0.85)
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)
Age⁵	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)
Blinatumomab	No (n=55)	40/54	⊢	0.74 (0.60-0.85)
Prior	Yes (n=52)	42/52	⊢	0.81 (0.67-0.90)
AlloSCT	No (n=98)	75/97	⊢	0.77 (0.68-0.85)
Extramedullary	Yes (n=32)	23/32	F	0.72 (0.53-0.86)
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)
Not in CR/CRi Prior to Infusion (n=96)		63/95	·	0.66 (0.56-0.76)
			0.60 0.70 0.80 0.90	
CR/CRi Rate (95% CI)				

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison

	No. of Patients with CR or CRi/Total No.ª							
Overall (N=150)		117/149	⊢	0.79 (0.71-0.85)				
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)				
Age⁵	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)				
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)				
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)				
Blinatumomab	No (n=55)	40/54	⊢	0.74 (0.60-0.85)				
Prior	Yes (n=52)	42/52	⊢−−−− 1	0.81 (0.67-0.90)				
AlloSCT	No (n=98)	75/97	⊢ I	0.77 (0.68-0.85)				
Extramedullary	Yes (n=32)	23/32	F	0.72 (0.53-0.86)				
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)				
Not in CR/CRi Pi		63/95	·•	0.66 (0.56-0.76)				
to Infusion (n=90	to Infusion (n=96)		0.60 0.70 0.80 0.90	1				
			CR/CRi Rate (95% CI)					

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison

	No. of Patients with CR or CRi/Total No.ª							
Overall (N=150)		117/149	⊢	0.79 (0.71-0.85)				
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)				
Age ^b	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)				
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)				
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)				
Blinatumomab	No (n=55)	40/54	⊢−−−− 1	0.74 (0.60-0.85)				
Prior	Yes (n=52)	42/52	⊢−−−− 1	0.81 (0.67-0.90)				
AlloSCT	No (n=98)	75/97	⊢	0.77 (0.68-0.85)				
Extramedullary	Yes (n=32)	23/32	F	0.72 (0.53-0.86)				
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)				
	Not in CR/CRi Prior		·•	0.66 (0.56-0.76)				
to Infusion (n=96)			0.60 0.70 0.80 0.90	-				
			CR/CRi Rate (95% CI)					

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison

	No. of Patients with CR or CRi/Total No.ª						
Overall (N=150)		117/149	F	0.79 (0.71-0.85)			
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)			
Age⁵	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)			
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)			
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)			
Blinatumomab	No (n=55)	40/54	F	0.74 (0.60-0.85)			
Prior	Yes (n=52)	42/52	↓	0.81 (0.67-0.90)			
AlloSCT	No (n=98)	75/97	F	0.77 (0.68-0.85)			
Extramedullary	Yes (n=32)	23/32	F1	0.72 (0.53-0.86)			
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)			
Not in CR/CRi Pi		63/95	·	0.66 (0.56-0.76)			
to Infusion (n=96	o)		0.60 0.70 0.80 0.90	1			
			CR/CRi Rate (95% CI)				

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison


	No. of Patients with CR or CRi/Total No.ª							
Overall (N=150)		117/149	F	0.79 (0.71-0.85)				
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)				
Age⁵	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)				
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)				
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)				
Blinatumomab	No (n=55)	40/54	⊢ I	0.74 (0.60-0.85)				
Prior	Yes (n=52)	42/52	⊢ •	0.81 (0.67-0.90)				
AlloSCT	No (n=98)	75/97	F	0.77 (0.68-0.85)				
Extramedullary	Yes (n=32)	23/32	۱	0.72 (0.53-0.86)				
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)				
	Not in CR/CRi Prior to Infusion (n=96)		·	0.66 (0.56-0.76)				
to infusion (n=90			0.60 0.70 0.80 0.90					
		CR/CRi Rate (95% CI)						

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison

	No. of Patients with CR or CRi/Total No.ª						
Overall (N=150)		117/149	⊢	0.79 (0.71-0.85)			
	≥26 Years (n=139)	109/138	⊢	0.79 (0.71-0.85)			
Age⁵	<60 Years (n=122)	93/121	⊢	0.77 (0.68-0.84)			
	≥60 Years (n=28)	24/28	⊢	0.86 (0.67-0.96)			
Prior	Yes (n=77)	64/77	⊢	0.83 (0.73-0.91)			
Blinatumomab	No (n=55)	40/54	⊢	0.74 (0.60-0.85)			
Prior	Yes (n=52)	42/52	⊢−−−− 1	0.81 (0.67-0.90)			
AlloSCT	No (n=98)	75/97		0.77 (0.68-0.85)			
Extramedullary	Yes (n=32)	23/32	۱	0.72 (0.53-0.86)			
Disease	No (n=101)	82/101	⊢	0.81 (0.72-0.88)			
Not in CR/CRi Pr		63/95	i −−−−•	0.66 (0.56-0.76)			
to Infusion (n=96)			0.60 0.70 0.80 0.90	-			
			CR/CRi Rate (95% CI)				

- The overall CR/CRi rate in the Effectiveness and Safety Analysis Set was 79% (66% in patients not in CR/CRi prior to infusion)
- CR/CRi rate was generally consistent across most subgroups, though a small number of patients in some subgroups limits comparison

DOR^a in the Effectiveness and Safety Analysis Set




- The median follow-up time was limited at 6.1 months
- The 6-month DOR rate in the Effectiveness and Safety Analysis Set was 72% (95% CI, 59-81)

^a Censored at subsequent alloSCT.

alloSCT, allogeneic stem cell transplant; DOR, duration of remission.

RFS^a in the Effectiveness and Safety Analysis Set




 The 6-month RFS rate in these patients was 56% (95% CI, 46-65)

^a Censored at subsequent alloSCT

alloSCT, allogeneic stem cell transplant; RFS, relapse-free survival.

OS in the Effectiveness and Safety Analysis Set



 The 6-month OS rate in these patients was 79% (95% Cl, 71-85)

OS, overall survival.

	All Patients	Age		Prior Blina	tumomab ^a	Prior AlloSCT	
	N=150	<60 Years (n=122)	≥60 Years (n=28)	Yes (n=77)	No (n=55)	Yes (n=52)	No (n=98)
6-Month DOR rate	72	80	47	62	80	81	64
(n=117), ^{b,c} % (95% Cl)	(59-81)	(69-88)	(19-71)	(42-77)	(59-90)	(62-91)	(44-78)
6-Month RFS rate, ^b %	56	60	43	52	58	64	50
(95% CI)	(46-65)	(50-68)	(20-64)	(37-65)	(44-70)	(49-76)	(36-62)
6-Month OS rate, %	79	80	71	77	82	79	78
(95% CI)	(71-85)	(72-86)	(48-85)	(66-86)	(68-90)	(65-88)	(69-86)
Subsequent alloSCT rate among responders (n=117), ^c % (95% CI)	30 (22-39)	35 (26-46)	8 (1-27)	34 (23-47)	23 (11-38)	10 (3-23)	41 (30-53)

• 6-month DOR, OS, and RFS rates were generally consistent across prior therapy subgroups

^a Prior blinatumomab treatment status not reported in 18 patients. ^b Censored at subsequent alloSCT. ^c Among patients who achieved CR/CRi as best response.

	All Patients	Age		Prior Blina	tumomab ^a	Prior AlloSCT	
	N=150	<60 Years (n=122)	≥60 Years (n=28)	Yes (n=77)	No (n=55)	Yes (n=52)	No (n=98)
6-Month DOR rate	72	80	47	62	80	81	64
(n=117), ^{b,c} % (95% Cl)	(59-81)	(69-88)	(19-71)	(42-77)	(59-90)	(62-91)	(44-78)
6-Month RFS rate, ^b %	56	60	43	52	58	64	50
(95% CI)	(46-65)	(50-68)	(20-64)	(37-65)	(44-70)	(49-76)	(36-62)
6-Month OS rate, %	79	80	71	77	82	79	78
(95% CI)	(71-85)	(72-86)	(48-85)	(66-86)	(68-90)	(65-88)	(69-86)
Subsequent alloSCT rate among responders (n=117), ^c % (95% CI)	30 (22-39)	35 (26-46)	8 (1-27)	34 (23-47)	23 (11-38)	10 (3-23)	41 (30-53)

• 6-month DOR, OS, and RFS rates were generally consistent across prior therapy subgroups

^a Prior blinatumomab treatment status not reported in 18 patients. ^b Censored at subsequent alloSCT. ^c Among patients who achieved CR/CRi as best response.

	All Patients	Age		Prior Blina	tumomabª	Prior AlloSCT	
	N=150	<60 Years (n=122)	≥60 Years (n=28)	Yes (n=77)	No (n=55)	Yes (n=52)	No (n=98)
6-Month DOR rate	72	80	47	62	80	81	64
(n=117), ^{b,c} % (95% Cl)	(59-81)	(69-88)	(19-71)	(42-77)	(59-90)	(62-91)	(44-78)
6-Month RFS rate, ^b %	56	60	43	52	58	64	50
(95% CI)	(46-65)	(50-68)	(20-64)	(37-65)	(44-70)	(49-76)	(36-62)
6-Month OS rate, %	79	80	71	77	82	79	78
(95% CI)	(71-85)	(72-86)	(48-85)	(66-86)	(68-90)	(65-88)	(69-86)
Subsequent alloSCT rate among responders (n=117), ^c % (95% CI)	30 (22-39)	35 (26-46)	8 (1-27)	34 (23-47)	23 (11-38)	10 (3-23)	41 (30-53)

• 6-month DOR, OS, and RFS rates were generally consistent across prior therapy subgroups

^a Prior blinatumomab treatment status not reported in 18 patients. ^b Censored at subsequent alloSCT. ^c Among patients who achieved CR/CRi as best response.

	All Patients	Age		Prior Blina	tumomabª	Prior AlloSCT	
	N=150	<60 Years (n=122)	≥60 Years (n=28)	Yes (n=77)	No (n=55)	Yes (n=52)	No (n=98)
6-Month DOR rate	72	80	47	62	80	81	64
(n=117), ^{b,c} % (95% Cl)	(59-81)	(69-88)	(19-71)	(42-77)	(59-90)	(62-91)	(44-78)
6-Month RFS rate, ^b %	56	60	43	52	58	64	50
(95% CI)	(46-65)	(50-68)	(20-64)	(37-65)	(44-70)	(49-76)	(36-62)
6-Month OS rate, %	79	80	71	77	82	79	78
(95% CI)	(71-85)	(72-86)	(48-85)	(66-86)	(68-90)	(65-88)	(69-86)
Subsequent alloSCT rate among responders (n=117), ^c % (95% CI)	30 (22-39)	35 (26-46)	8 (1-27)	34 (23-47)	23 (11-38)	10 (3-23)	41 (30-53)

• 6-month DOR, OS, and RFS rates were generally consistent across prior therapy subgroups

^a Prior blinatumomab treatment status not reported in 18 patients. ^b Censored at subsequent alloSCT. ^c Among patients who achieved CR/CRi as best response.

	All Patients	Age		Prior Blina	tumomab ^a	Prior AlloSCT	
	N=150	<60 Years (n=122)	≥60 Years (n=28)	Yes (n=77)	No (n=55)	Yes (n=52)	No (n=98)
6-Month DOR rate	72	80	47	62	80	81	64
(n=117), ^{b,c} % (95% Cl)	(59-81)	(69-88)	(19-71)	(42-77)	(59-90)	(62-91)	(44-78)
6-Month RFS rate, ^b %	56	60	43	52	58	64	50
(95% CI)	(46-65)	(50-68)	(20-64)	(37-65)	(44-70)	(49-76)	(36-62)
6-Month OS rate, %	79	80	71	77	82	79	78
(95% CI)	(71-85)	(72-86)	(48-85)	(66-86)	(68-90)	(65-88)	(69-86)
Subsequent alloSCT rate among responders (n=117), ^c % (95% CI)	30 (22-39)	35 (26-46)	8 (1-27)	34 (23-47)	23 (11-38)	10 (3-23)	41 (30-53)

 30% (95% CI, 22-39) of responders (n=117) went on to subsequent alloSCT with a median time to alloSCT of 102 days (range, 47-297), and this was consistent among patients with and without prior blinatumomab and patients aged <60 years

^a Prior blinatumomab treatment status not reported in 18 patients. ^b Censored at subsequent alloSCT. ^c Among patients who achieved CR/CRi as best response.

	Extramedullary Disease ^a		CNS D	iseaseª	MRD Status Prior to Infusion ^b		
	Yes (n=32)	No (n=101)	Yes (n=14)	No (n=118)	CR/CRi MRD+ ^c (n=11)	CR/CRi MRD– ^d (n=36)	Not in CR/CRi (n=96)
6-Month DOR rate (n=117), ^{e,f}	85	70	80	71	64	66	75
% (95% CI)	(60-95)	(54-81)	(41-95)	(56-82)	(22-87)	(44-81)	(53-88)
6 Month RES rate 8 % (DE% CI)	59	56	54	57	64	66	48
6-Month RFS rate, ^e % (95% CI)	(39-75)	(44-67)	(23-77)	(46-67)	(22-87)	(45-81)	(37-59)
6 Month OS rate $%$ (05% Cl)	68	83	64	81	91	87	75
6-Month OS rate, % (95% CI)	(47-82)	(74-89)	(29-85)	(72-87)	(51-99)	(67-95)	(64-83)
Subsequent alloSCT rate among	30	30	10	32	9	28	32
responders (n=117), ^f % (95% Cl)	(13-53)	(21-42)	(<1-45)	(23-42)	(<1-41)	(14-45)	(21-45)

• 6-month DOR, OS, and RFS rates were generally consistent across disease status subgroups

	Extramedullary Disease ^a		CNS D	iseaseª	MRD Status Prior to Infusion ^b		
	Yes (n=32)	No (n=101)	Yes (n=14)	No (n=118)	CR/CRi MRD+° (n=11)	CR/CRi MRD– ^d (n=36)	Not in CR/CRi (n=96)
6-Month DOR rate (n=117), ^{e,f}	85	70	80	71	64	66	75
% (95% CI)	(60-95)	(54-81)	(41-95)	(56-82)	(22-87)	(44-81)	(53-88)
6 Month RES rate 8 % (OE% CI)	59	56	54	57	64	66	48
6-Month RFS rate, ^e % (95% CI)	(39-75)	(44-67)	(23-77)	(46-67)	(22-87)	(45-81)	(37-59)
6 Month OS rate 9/ (059/ CI)	68	83	64	81	91	87	75
6-Month OS rate, % (95% CI)	(47-82)	(74-89)	(29-85)	(72-87)	(51-99)	(67-95)	(64-83)
Subsequent alloSCT rate among	30	30	10	32	9	28	32
responders (n=117), ^f % (95% Cl)	(13-53)	(21-42)	(<1-45)	(23-42)	(<1-41)	(14-45)	(21-45)


• 6-month DOR, OS, and RFS rates were generally consistent across disease status subgroups

	Extramedullary Disease ^a		CNS Disease ^a		MRD Status Prior to Infusion ^b		
	Yes (n=32)	No (n=101)	Yes (n=14)	No (n=118)	CR/CRi MRD+° (n=11)	CR/CRi MRD- ^d (n=36)	Not in CR/CRi (n=96)
6-Month DOR rate (n=117), ^{e,f}	85	70	80	71	64	66	75
% (95% CI)	(60-95)	(54-81)	(41-95)	(56-82)	(22-87)	(44-81)	(53-88)
6-Month RFS rate, ^e % (95% Cl)	59	56	54	57	64	66	48
	(39-75)	(44-67)	(23-77)	(46-67)	(22-87)	(45-81)	(37-59)
6-Month OS rate, % (95% CI)	68	83	64	81	91	87	75
	(47-82)	(74-89)	(29-85)	(72-87)	(51-99)	(67-95)	(64-83)
Subsequent alloSCT rate among	30	30	10	32	9	28	32
responders (n=117), ^f % (95% Cl)	(13-53)	(21-42)	(<1-45)	(23-42)	(<1-41)	(14-45)	(21-45)


• 6-month DOR, OS, and RFS rates were generally consistent across disease status subgroups

	Extramedullary Disease ^a		CNS Disease ^a		MRD Status Prior to Infusion ^b		
	Yes (n=32)	No (n=101)	Yes (n=14)	No (n=118)	CR/CRi MRD+° (n=11)	CR/CRi MRD– ^d (n=36)	Not in CR/CRi (n=96)
6-Month DOR rate (n=117), ^{e,f}	85	70	80	71	64	66	75
% (95% CI)	(60-95)	(54-81)	(41-95)	(56-82)	(22-87)	(44-81)	(53-88)
6-Month RFS rate, ^e % (95% Cl)	59	56	54	57	64	66	48
	(39-75)	(44-67)	(23-77)	(46-67)	(22-87)	(45-81)	(37-59)
6-Month OS rate, % (95% CI)	68	83	64	81	91	87	75
	(47-82)	(74-89)	(29-85)	(72-87)	(51-99)	(67-95)	(64-83)
Subsequent alloSCT rate among	30	30	10	32	9	28	32
responders (n=117), ^f % (95% CI)	(13-53)	(21-42)	(<1-45)	(23-42)	(<1-41)	(14-45)	(21-45)

 The subsequent alloSCT rate among responders was consistent with the overall population among patients with and without extramedullary disease, patients without CNS disease, patients in CR/CRi after prior therapy who were MRD–, and patients not in CR/CRi after prior therapy



^a CRS and ICANS were graded per ASTCT consensus criteria.



 Among patients with 0% to <5% bone marrow blasts prior to infusion (n=65), 10 patients (15%) had Grade ≥3 ICANS (data not shown)

^a CRS and ICANS were graded per ASTCT consensus criteria.

Parameter	All Patients (N=150)
Median time from infusion to CRS onset (range), ^{a,b} days	6.0 (1.0-14.0)
Median time from CRS onset to resolution (range), ^{a,b} days	6.0 (1.0-27.0)
Median time from infusion to ICANS onset (range), ^{a,b} days	8.0 (2.0-16.0)
Median time from ICANS onset to resolution (range), ^{a,b} days	6.0 (1.0-68.0)
Corticosteroids to treat CRS or ICANS, n (%)	75 (50)
Tocilizumab to treat CRS or ICANS, n (%)	96 (64)

 Median time to resolution for both CRS and ICANS was 6.0 days, with 94% and 80% resolved by Week 3, respectively


^a CRS and ICANS were graded per ASTCT consensus criteria. ^b Among patients who reported any-grade CRS/ICANS at Day 100 follow-up.

Parameter	All Patients (N=150)
Median time from infusion to CRS onset (range), ^{a,b} days	6.0 (1.0-14.0)
Median time from CRS onset to resolution (range), ^{a,b} days	6.0 (1.0-27.0)
Median time from infusion to ICANS onset (range), ^{a,b} days	8.0 (2.0-16.0)
Median time from ICANS onset to resolution (range), ^{a,b} days	6.0 (1.0-68.0)
Corticosteroids to treat CRS or ICANS, n (%)	75 (50)
Tocilizumab to treat CRS or ICANS, n (%)	96 (64)

 Median time to resolution for both CRS and ICANS was 6.0 days, with 94% and 80% resolved by Week 3, respectively

^a CRS and ICANS were graded per ASTCT consensus criteria. ^b Among patients who reported any-grade CRS/ICANS at Day 100 follow-up.

Prolonged Cytopenias^a in All Patients



 Prolonged (present at Day 30 after infusion) Grade 4 thrombocytopenia and neutropenia occurred in 31% and 33% of patients, respectively

^a Present at Day 30 after infusion among the 141 patients who survived Day 30. Prolonged cytopenia is defined as having either prolonged Grade 4 neutropenia (failure to recover ANC ≥500/mm³ (0.5×10⁹/L) and/or sustain 3 lab values within the first 30 days after infusion) or prolonged Grade 4 thrombocytopenia (failure to recover platelet count ≥20×10⁹/L within the first 30 days after infusion). ANC, absolute neutrophil count.

Adverse Events of Interest, n (%)	All Patients (N=150)
Clinically significant infections ^a	76 (51)
Bacterial	46 (31)
Fungal	11 (7)
Viral	34 (23)
Other	15 (10)
Deaths	38 (25)
Deaths ≤3 months after brexu-cel infusion, n (%)	22 (15)
Deaths ≤1 month after brexu-cel infusion, n (%)	9 (6)
Deaths >1 month and ≤3 months after brexu-cel infusion, n (%)	13 (9)

• Clinically significant infections occurred in 51% of patients, with most being bacterial or viral

Adverse Events of Interest, n (%)	All Patients (N=150)
Clinically significant infections ^a	76 (51)
Bacterial	46 (31)
Fungal	11 (7)
Viral	34 (23)
Other	15 (10)
Deaths	38 (25)
Deaths ≤3 months after brexu-cel infusion, n (%)	22 (15)
Deaths ≤1 month after brexu-cel infusion, n (%)	9 (6)
Deaths >1 month and ≤3 months after brexu-cel infusion, n (%)	13 (9)

• Clinically significant infections occurred in 51% of patients, with most being bacterial or viral

Adverse Events of Interest, n (%)	All Patients (N=150)
Clinically significant infections ^a	76 (51)
Bacterial	46 (31)
Fungal	11 (7)
Viral	34 (23)
Other	15 (10)
Deaths	38 (25)
Deaths ≤3 months after brexu-cel infusion, n (%)	22 (15)
Deaths ≤1 month after brexu-cel infusion, n (%)	9 (6)
Deaths >1 month and ≤3 months after brexu-cel infusion, n (%)	13 (9)

• Of the 38 patients who died, 22 died within 3 months of brexu-cel infusion (including 9 who died within 1 month)

Adverse Events of Interest, n (%)	All Patients (N=150)
Clinically significant infections ^a	76 (51)
Bacterial	46 (31)
Fungal	11 (7)
Viral	34 (23)
Other	15 (10)
Deaths	38 (25)
Deaths ≤3 months after brexu-cel infusion, n (%)	22 (15)
Deaths ≤1 month after brexu-cel infusion, n (%)	9 (6)
Deaths >1 month and ≤3 months after brexu-cel infusion, n (%)	13 (9)

• Of the 38 patients who died, 22 died within 3 months of brexu-cel infusion (including 9 who died within 1 month)

 This real-world study of adult patients with R/R B-ALL treated with brexu-cel demonstrated promising effectiveness outcomes, with a 79% CR/CRi rate and a 6-month OS rate of 79%

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; OS, overall survival; R/R, relapsed or refractory.

- This real-world study of adult patients with R/R B-ALL treated with brexu-cel demonstrated promising effectiveness outcomes, with a 79% CR/CRi rate and a 6-month OS rate of 79%
- Effectiveness outcomes were largely consistent across subgroups

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; OS, overall survival; R/R, relapsed or refractory.

- This real-world study of adult patients with R/R B-ALL treated with brexu-cel demonstrated promising effectiveness outcomes, with a 79% CR/CRi rate and a 6-month OS rate of 79%
- Effectiveness outcomes were largely consistent across subgroups
- The safety profile of brexu-cel in the real-world setting was manageable (9% Grade ≥3 CRS and 23% Grade ≥3 ICANS) and consistent with the safety profile in the clinical trial setting

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; OS, overall survival; R/R, relapsed or refractory.

- This real-world study of adult patients with R/R B-ALL treated with brexu-cel demonstrated promising effectiveness outcomes, with a 79% CR/CRi rate and a 6-month OS rate of 79%
- Effectiveness outcomes were largely consistent across subgroups
- The safety profile of brexu-cel in the real-world setting was manageable (9% Grade ≥3 CRS and 23% Grade ≥3 ICANS) and consistent with the safety profile in the clinical trial setting
- Future analyses with longer follow-up and larger sub-groups of interest are planned

B-ALL, B-cell acute lymphocytic leukemia; brexu-cel, brexucabtagene autoleucel; CR, complete remission; CRi, complete remission with incomplete hematological recovery; CRS, cytokine release syndrome; ICANS, immune effector cell–associated neurotoxicity syndrome; OS, overall survival; R/R, relapsed or refractory.

Acknowledgments

- The patients, families, friends, and caregivers
- The study investigators, coordinators, and healthcare staff at each study site
- Medical writing support was provided by Edward Sheetz, PhD, of Nexus Global Group Science, funded by Kite, a Gilead Company
- This study was funded by the National Cancer Institute (CIDR [U24 CA233032]) and Kite, a Gilead Company
- Full author disclosures are available through the virtual meeting platform

This study is a collaboration between CIBMTR[®] and Kite, a Gilead Company. CIBMTR[®] is a research collaboration between National Marrow Donor Program[®] and the Medical College of Wisconsin



CIBMTR[®] & Kite, a Gilead Company Collaboration Study